The abstract is read at the publisher; the summary is JClub's.
CRISPR/SaCas9 AURKA knockdown in HepG2 hepatocellular carcinoma cells induces indels that cause G2-phase cell cycle arrest and slight apoptosis activation.
- Why it matters: AURKA is overexpressed in HCC and linked to poor prognosis and treatment resistance, but its mechanistic contribution to cell-cycle control and therapy response needs clearer genetic evidence.
- What they did: Bioinformatics linked AURKA overexpression to mitotic proteins and oncogenes; in HepG2, CRISPR/SaCas9 disruption reduced AURKA and shifted p21/p53/caspase-8 up while CDK1/CDK2/PI3K (alpha subunit)/P38/BCL-2 down, confirmed by flow cytometry and scratch/colony assays.
- The result: AURKA suppression also modulates PI3K/AKT and p38/MAPK pathways and, when combined with Lenvatinib, significantly reduces HepG2 cell viability versus either treatment alone.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.